

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/509127-Conf. #4051	
			Filing Date	September 28, 2004	
			First Named Inventor	Piotr GRACZYK	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	0102286.00152US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Y ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
JB	BA	WO-0035909-A1	06-22-2000	F. Hoffman - La Roche AG		✓
	BB	WO-0035921-A1	06-22-2000	F. Hoffman - La Roche AG		✓
	BC	WO-0056710-A1	09-28-2000	Glaxo Group Limited		✓
	BD	WO-0112609-A1	02-22-2001	Signal Pharmaceuticals		✓
	BE	WO-0147922-A2	07-05-2001	Aventis Pharma Ltd.		✓
	BF	WO-0149288-A1	07-12-2001	Canada, et al.		✓
	BG	WO-02081475-A1	10-17-2002	Eisai Co. Ltd.		✓
	BH	WO-0216359-A1	02-28-2002	Glaxo Group Limited		✓
	BI	WO-03082869-A1	10-09-2003	Eisai London		
	BJ	EP-0737685-A1	10-16-1996	Adir et Compagnie		
	BK	EP-1106621-A2	06-13-2001	Fuji Photo Film Co., Ltd.		✓
JB	BL	WO-9921859-A1	05-06-1999	Glaxo Group Limited		✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Y ²
JB	CA	Cao, J. et al., "Distinct Requirements for p38 α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Difference Forms of Apoptotic Neuronal Death." <i>The Journal of Biological Chemistry</i> . 2004. Vol. 279, No. 34, 359033-13.	
	CB	Eilers, A. et al., "Direct inhibition of c-Jun N-terminal kinase in sympathetic neurons prevents c-jun promoter activation and NGF withdrawal-induced death" <i>Journal of Neurochemistry</i> . 1998. 76, 1439-54.	
	CC	Eilers, A. et al., "Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons" <i>The Journal of Neuroscience</i> . 1998. 8(5), 1713-24.	
	CD	Estus, S. et al., "Aggregated Amyloid- β Protein Induces Cortical Neuronal Apoptosis and Concomitant "Apoptotic" Pattern of Gene Induction." <i>The Journal of Neuroscience</i> . 1997. 17(20), 7736-45.	
	CE	Ham, J. et al., "A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death" <i>Neuron</i> . 1995. Vol. 14, 927-39.	
	CF	Lisnock, J. et al., "Activation of JNK3 α 1 Requires both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3 α 1" <i>Biochemistry</i> . 2000. Vol. 39, 3141-48.	
JB	CG	Watson, A. et al., "Phosphorylation of c-Jun Is Necessary for Apoptosis Induced by Survival	

Examiner Signature	/Robert Balls/	Date Considered	11/07/2006
-----------------------	----------------	--------------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/509127-Conf. #4051
				Filing Date	September 28, 2004
				First Named Inventor	Piotr GRACZYK
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0102286.00152US1

JB		Signal Withdrawal in Cerebellar Granule Neurons* <i>The Journal of Neuroscience</i> . 1998. 18(2), 751-62.	
JB	CH	Young, P. R. et al., "Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site" <i>The Journal of Biological Chemistry</i> , 1997. Vol. 272, No. 18, 12116-21.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Robert Balls/	Date Considered	11/07/2006
-----------------------	----------------	--------------------	------------